Pharmaceuticals, Biotechnology & Life Sciences

Medicenna Therapeutics: Investor beware – high‑risk biotech focused on CNS & urological cancer therapies faces steep financial struggles and stock volatility. Learn why growth depends on clinical breakthroughs.

EyePoint Pharmaceuticals’ DURAVYU failed in the Phase‑3 LUGANO trial, sparking a 70% share drop and investor fraud investigations—learn how to file a claim and seek recovery.

Auxly Cannabis Group hits a 12‑month high at CAD 3.15, showcasing strong, stable financials and a unique investment model that fuels growth in the cannabis‑healthcare sector.

Tezspire’s Phase‑III win in eosinophilic esophagitis marks AstraZeneca’s breakthrough in rare‑disease therapy, boosting its growth prospects and dividend outlook.

Ascelia Pharma AB is pushing biotech innovation, focusing on liver metastases and gastric cancer treatments in Sweden, while navigating volatile stock and R&D‑heavy growth prospects.

Shenqi Pharmaceutical’s 10.05% surge on 27 Aug, 2026, set a new record with 15 B CNY volume, marking an 11‑day, 7‑board streak amid China’s pharma rally.

Harbin Pharmaceutical Group discloses 2026 mid‑year results, new accounting policies and an impairment reserve, showcasing transparency and strategic growth in China’s pharma market.

Medexus Pharmaceuticals stock dips below its 52‑week high: Learn why investors worry about its negative P/E, and how its focus on rheumatology, oncology and pediatrics could drive future growth.

Oxford Nanopore’s 60% monthly rally shows its new licensing strategy and sharp earnings turnaround, turning a tarnished reputation into a top FTSE 350 performer.

Explore Harbin Gloria Pharmaceuticals: a mid‑cap Chinese pharma with steady injectable and oral products, solid fundamentals but limited growth excitement.